title: Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer.
abstract: Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey. fsbiricik@yahoo.com.
authors.forename: F
authors.initials: F
authors.lastname: Selcukbiricik
authors.affiliation: Department of Nephrology, Faculty of Medicine, Koc University, Istanbul, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Kanbay
authors.affiliation: Department of Nephrology, Sakarya Education and Research Hospital, Korucuk, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Solak
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Bilici
authors.affiliation: Department of Medical Oncology, Hamidiye Sisli Education and Research Hospital, Istanbul, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Kanıtez
authors.affiliation: Department of General Surgery, Faculty of Medicine, Koc University, Istanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Balık
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey.|Department of Medical Oncology, VKV American Hospital, Istanbul, Turkey.
authors.forename: N M
authors.initials: NM
authors.lastname: Mandel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D015331:Cohort Studies; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014527:Uric Acid / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D014527:Uric Acid; D000068258:Bevacizumab
keywords: Bevacizumab; Carcinoembryonic antigen; Hypoxia; Metastatic colorectal cancer; Survival; Uric acid